Pediatrix Welcomes Two Nationally Renowned Physician Leaders Mar 24, 2026 5:10 PM Eastern Daylight Time Share Pediatrix Welcomes Two Nationally Renowned Physician Leaders Dr. James Barry, who will join as Chief Clinical Quality & Transformation Officer, and Dr. Jochen Profit, who will serve as Chief Quality Advisor, bring extraordinary reputations as care quality experts FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pediatrix® Medical Group, Inc. (NYSE: MD), a leading provider of physician services, is pleased to ...

Key Takeaways Pediatrix Medical benefits from a favorable payer mix and higher neonatology patient acuity.MD 2026 EPS estimated at $2.18, up 6.9% year over year, with stable RCM collections aiding performance.Pediatrix Medical trades at 9.39X forward P/E, below its five-year mean and the industry average.Pediatrix Medical Group, Inc. (MD) is well-poised to grow on the back of a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are expected to increase its capacity and volu ...

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through various research services [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [3] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [4] - The Growth Score evaluates a company's future prospects through projected earnings and sales growth [5] - The Momentum Score identifies stocks with upward or downward trends based on recent price changes and earnings estimates [6] - The VGM Score combines the three Style Scores to highlight stocks with attractive value, growth potential, and positive momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.86% since 1988, outperforming the S&P 500 [8] - There are typically over 800 stocks rated 1 or 2, making it essential to utilize Style Scores for effective stock selection [9] - For optimal returns, stocks should ideally have a Zacks Rank of 1 or 2 along with Style Scores of A or B [10] Stock Highlight: Pediatrix Medical Group - Pediatrix Medical Group, trading under the ticker MD, is currently rated 3 (Hold) with a VGM Score of A [12] - The company is projected to have a year-over-year earnings growth of 2% for the current fiscal year, with a recent increase in earnings estimates [13] - MD has an average earnings surprise of +24.6%, making it a strong candidate for growth investors [13]

Figure 1 MD Projects-Eeyou Istchee James Bay Figure 2 Caniaspic Au 2025 Results Figure 3 Caniapisc Au Planned IP Figure 4 Samples 2025 Figure 5 Samples 2025 Figure 6 Samples 2025 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an induced polarization ground (“IP’) geophysical survey on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions. The Caniapisc Au project is wholly ...

Core Insights - Pediatrix Medical Group reported a consolidated revenue decline year over year, primarily due to $26 million in net non-same-unit activity related to portfolio restructuring, although same-unit revenue grew by 4% with pricing up nearly 7% and patient service volumes down just under 3% [1][5] Financial Performance - The company achieved adjusted EBITDA of $66 million in Q4 and $276 million for the full year 2025, reflecting strong operating trends and record practice bonuses [1][5] - Operating cash flow for Q4 was $115 million, down from $135 million in the prior year, attributed to decreases in cash flow from accounts payable and accrued liabilities [8] - Pediatrix ended the quarter with approximately $375 million in cash and net debt of just over $220 million, resulting in a net leverage of just under 1x [9] 2026 Outlook - Management guided for 2026 adjusted EBITDA in the range of $280 million to $300 million, which is about 5% above 2025 at the midpoint, with full-year revenue expected to be approximately $1.9 billion, flat year-over-year [4][11] - The outlook assumes steady metrics, including volume and payer mix, and does not include contributions from potential M&A [4][13] Strategic Initiatives - Pediatrix introduced physician alignment programs with over 500 physicians participating, aimed at enhancing care quality and shared responsibility [3][17] - The company plans to pursue opportunistic stock buybacks and selective M&A while maintaining a focus on balance sheet strength [20][21] Cost Management - Practice-level salaries, wages, and benefits slightly declined year over year, reflecting portfolio restructuring, while general and administrative expenses increased due to higher salary and travel expenses [6][7] - The company anticipates a reduction in G&A expenses as a percentage of revenue for 2026, with full-year G&A expected to be between $230 million and $240 million [12]

Core Insights - Pediatrix Medical Group has announced the 47th Annual NEO: The Conference for Neonatology, highlighting its commitment to advancing neonatal care and education [1] Company Overview - Pediatrix Medical Group is focused on providing specialized medical services for neonatology, emphasizing the importance of ongoing education and professional development in the field [1] Industry Context - The conference serves as a significant platform for healthcare professionals in neonatology to share knowledge, discuss advancements, and collaborate on best practices, reflecting the industry's dedication to improving neonatal outcomes [1]

Core Insights - Pediatrix Medical Group, Inc. reported fourth-quarter 2025 adjusted EPS of 50 cents, missing the Zacks Consensus Estimate by 4.9%, with a year-over-year decline of 2% [1] - Net revenues for the quarter decreased by 1.7% year over year to $493.8 million, slightly exceeding the Zacks Consensus Estimate by 0.5% [1] Financial Performance - Full-year 2025 net revenues totaled $1.9 billion, a decline of 4.9% year over year, aligning with the Zacks Consensus Estimate [5] - Adjusted EPS for the full year was $2.04, reflecting a 35.1% increase year over year, but missing the Zacks Consensus Estimate of $2.07 [5] - Full-year adjusted EBITDA was $275.6 million, up 23% year over year, while total operating expenses decreased by 18.1% to $1.7 billion [6] Revenue and Expense Analysis - Same-unit revenues increased by 4% year over year in Q4 2025, falling short of the growth estimate and Zacks Consensus Estimate of 6.8% [7] - Same-unit revenues from net reimbursement-related factors grew by 6.7% year over year, driven by improved patient acuity and favorable collection activity, exceeding both the Zacks Consensus Estimate and internal model estimates [8] - Total operating expenses for Q4 were $445 million, down 3.9% year over year, but higher than the estimated $415.4 million [10] Cash Flow and Share Repurchase - As of December 31, 2025, Pediatrix Medical had cash and cash equivalents of $375.2 million, up from $229.9 million a year prior, with no outstanding borrowings on its revolving credit facility [12] - The company repurchased 4.1 million shares for $83.8 million during 2025, with $166.2 million remaining available in the buyback program [14] 2026 Outlook - Management projects adjusted EBITDA for 2026 to be between $280 million and $300 million, with net income estimated between $155.1 million and $169.7 million [15] - Interest expenses are forecasted at $34 million, with income tax expenses expected to range from $57.4 million to $62.8 million [15]

Core Insights - Pediatrix Medical Group's shares fell over 12% following its earnings report, indicating market disappointment with the results [1] Financial Performance - In Q4, Pediatrix reported revenue of nearly $493.8 million, a decrease of almost 2% year-over-year [2] - Non-GAAP net income fell to $42.5 million ($0.50 per share) from $43.5 million in the previous year [2] - Analysts had expected lower revenue of $486.2 million but higher profitability, with a consensus for non-GAAP net income at $0.54 per share [3] Cost and Profitability Concerns - The company's profitability was negatively impacted by increased bonus payouts to practitioners due to a tightening labor market [3] - Despite challenges, Pediatrix has historically managed to deliver growth and maintain decent profits [5] Future Guidance - Pediatrix provided selective guidance, expecting adjusted EBITDA of $280 million to $300 million for full-year 2026, up from $275.6 million the previous year [4] Investment Sentiment - Given the anticipated tepid growth figures, the company is not viewed as a compelling buy, even after the recent price drop [5] - Pediatrix Medical Group was not included in a list of top stocks recommended by analysts, suggesting a cautious outlook for potential investors [6]

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [5][6] - The consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with pricing up just under 7% [7][8] - Operating cash flow for Q4 was $115 million, down from $135 million in the prior year, primarily due to decreases in cash flow from accounts payable and accrued liabilities [9] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [7][8] - Despite volume declines across service lines, pricing was driven by solid revenue cycle management cash collections and favorable payer mix [7][8] Market Data and Key Metrics Changes - The company anticipates full-year revenue for 2026 to be approximately $1.9 billion, in line with 2025 [10] - The G&A expense for 2026 is projected to be between $230 million and $240 million, compared to $241 million in 2025 [10] Company Strategy and Development Direction - The company is focusing on quality care and has introduced new programs to align physicians with the organization, including cash bonuses and stock price tracking elements [12][13] - There are plans to leverage telemedicine and expand in NICUs and maternal-fetal medicine, with a strong presence in OB hospital medicine [14][15] Management's Comments on Operating Environment and Future Outlook - Management expects steady metrics for 2026, including volume, acuity, and payer mix, with a preliminary outlook of adjusted EBITDA between $280 million and $300 million [6][10] - The company is monitoring potential impacts from ACA subsidies and government enrollment changes, but currently sees no significant changes in payer mix [29][30] Other Important Information - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [9] - The company has not factored any contributions from M&A activity into the 2026 guidance but is open to opportunities that align with its core strengths [11][41] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management indicated that the revenue growth assumes flat volume and pricing, with no significant changes expected [18] Question: Reasons for negative patient volume year-over-year - The decrease in volume was attributed to tough comparisons from the previous year's fourth quarter [20] Question: Details on variable compensation expenses - Management noted that various factors influenced fourth-quarter operations, emphasizing alignment with physicians rather than smoothing effects [26] Question: Insights on pricing strength and sustainability - Pricing was up just under 7%, driven by strong RCM collections and favorable payer mix, with expectations for stability moving into 2026 [47][50]

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [5][6] - The company expects 2026 adjusted EBITDA to be in the range of $280 million to $300 million, representing a 5% increase from 2025 [6][10] - Consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with pricing up just under 7% [7][10] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [7][8] - Variable practice incentive compensation and salary and benefits increased on a same-unit basis, while G&A expenses rose year-over-year due to salary and travel expenses [8][9] Market Data and Key Metrics Changes - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [9] - The accounts receivable days sales outstanding (AR DSO) improved to 42.8 days, down almost five days year-over-year [9] Company Strategy and Development Direction - The company introduced new programs to align physicians with cash bonuses and stock price tracking elements, aiming to enhance care quality and organizational alignment [12][13] - Pediatrix is focusing on leveraging telemedicine and expanding its presence in OB hospital medicine, with plans for growth in NICUs and maternal-fetal medicine [13][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the operating environment remains stable, with expectations for steady metrics in 2026, although potential impacts from ACA subsidies are acknowledged [6][10] - The company is committed to maintaining its balance sheet strength and will only consider growth opportunities that do not dilute its core pediatrics and obstetrics strengths [15][41] Other Important Information - The company plans to update on potential M&A activity in 2026, with a focus on maintaining its core strengths while exploring growth opportunities [11][41] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management indicated that revenue growth is expected to be flat in both volume and pricing for 2026 [18][19] Question: Reasons for negative patient volume year-over-year - Management attributed the decline in patient volume to tough comparisons from Q4 of the previous year [20][21] Question: Details on variable compensation expenses - Management noted that various factors influenced Q4 operations, emphasizing alignment rather than smoothing effects for future years [25][26] Question: Guidance on pricing and payer mix - Management confirmed that pricing is expected to remain steady, with no significant changes anticipated in payer mix for 2026 [30][31] Question: G&A cost reduction assumptions - Management acknowledged a small expected decline in G&A expenses year-over-year, with no specific factors identified [37][38] Question: Share repurchase plans - Management indicated a smaller amount of stock buyback is anticipated in the current guidance compared to 2025 [39][40] Question: Sustainability of pricing strength - Management highlighted strong RCM collections and favorable payer mix as key drivers of pricing strength, with expectations for stability moving into 2026 [45][46]